**March 3, 2017**

## Amendments to CLIN Program Announcements

The CIRM Governing Board approved several concept amendments to the ongoing Clinical ("CLIN") program on February 23, 2017 that will be applied to applications submitted **after March 31, 2017**.

The CLIN program announcements dated March 3, 2017 have been revised with the following amendments:

1. **CIRM Eligibility Determination**

We have clarified that CIRM has the authority to terminate work on an award up until the time a contract is executed for failure to meet one or more eligibility criteria, with the exception of those clinical program criteria designated as subjective. CIRM will inform the Application Review Subcommittee at its next public meeting whenever CIRM makes an eligibility determination following approval by the Application Review Subcommittee.

2. **Good Standing Eligibility Requirement**

CIRM may disqualify an applicant if CIRM determines that: (1) for for-profits, and non-profits in existence for less than five years, the applicant did not have adequate financial systems in place to track CIRM funds, or the applicant's chief executive officer, chief financial officer, or principal investigator has been convicted of, or is currently under investigation for, crimes involving fraud or misappropriation of funds; and (2) for all applicants, the principal investigator is currently under investigation for research misconduct or is barred from receiving research funds by the Health and Human Services Office of Research Integrity.

3. **Eligibility for Small Molecule or Biologic where a Stem Cell is Necessary to Manufacture the Therapy or that Modifies the Stem Cell Therapy**

We have clarified that research involving small molecules or biologics for which a stem cell is necessary to manufacture the therapy is also eligible for funding under CIRM's CLIN 1 program (e.g., exosomes manufactured from a stem cell).

In addition, we have clarified that research involving small molecules or biologics that are intended to modify a stem cell therapy, such as a cell tracking agent, are eligible.

4. **Program Manager Eligibility Requirement**

Applicants are required to include a project manager on the applicant team to help ensure that the project stays on track and meets its milestones. Rather than requiring applicants to designate an employee or hire an independent contractor, CIRM will now allow applicants to satisfy this requirement by entering into a contract with CIRM's Stem Cell Center to provide project management services.

5. **Principal Investigator Percent Effort**

Previously, CIRM required principal investigators to commit to a minimum effort of 30%. Because the percent effort required by the principal investigator, especially for a clinical trial, may be less and it may vary over time, CIRM will now require that the PI justify a percent effort consistent with achieving the project's aims but must not be less than an average of 15% over the project period.

6. **CLIN1 Readiness Requirement to File an IND within 18 Months**

The CLIN 1 PA previously required that applicants be prepared to file an IND within 24 months of commencing work on the project. CIRM's strategic plan goal, however, is to accelerate the time it takes a stem cell treatment to move from discovery into a clinical trial by 50%. In order to accomplish this goal, we must ensure that CLIN 1 awardees are prepared to file an IND/IDE with the Food and Drug Administration within 18 months of starting work on the project. Therefore, the readiness eligibility requirement for CLIN 1 applicants has been reduced from 24 months to 18 months.

7. **Clinical Trial Eligibility**

Although eligibility for phase 1 clinical trials will continue to include projects proposing to study therapeutic products classified as small molecules, biologics, devices and cell therapies, eligibility for phase 2 and 3 trials is now limited to cellular therapies where stem or progenitor cells either comprise the therapy or are used to manufacture the cell therapy. For Phase 3 trials, reviewers will be directed to give a preference to cell therapies that address pediatric or orphan diseases.

**8. Eligibility for CLIN 3**

The CLIN 3 program announcement has been substantially changed and it is now limited to existing clinical trial (CLIN2) awardees to support new activities on the awardee's active project that would, if successful, enable the awardee to attain marketing approval of the proposed stem cell treatment with the Food and Drug Administration (FDA).

**9. Fundable Activities**

CIRM will allow, where it is necessary and appropriate justification has been provided, the cost to manufacture product beyond what is necessary for the immediate trial supported under the award.

For CLIN 2, fundable activities may now include comparability studies and commercial development activities.

In addition, we have clarified that allowable project costs for a non-California organization that conducts clinical trials in California include the per subject share of the costs of treating California subjects, including costs incurred out- of-state.

**10. Eligibility for Devices**

Previously, CIRM imposed no limits on funding for device trials. In light of CIRM's limited funding and the well-defined regulatory pathway for devices, CIRM will now limit device trials to feasibility. Therefore, CIRM funds are not available for a pivotal trial for a device.